A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

Abstract Background Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen, an orally administered small molecule, binds to an iron-responsive element in APP mRNA and decreases translat...

Full description

Bibliographic Details

Published in:	Alzheimer’s Research & Therapy
Main Authors:	Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig, Donald Elbert, Randall Bateman, Jeremiah Momper, Ronald G. Thomas, Robert A. Rissman, Judy Pa, Vahan Aslanyan, Archana Balasubramanian, Tim West, Maria Maccecchini, Howard H. Feldman
Format:	Article
Language:	English
Published:	BMC 2024-07-01
Subjects:	Alzheimer’s disease Amyloid beta protein APP Pharmacodynamics Clinical trial
Online Access:	https://doi.org/10.1186/s13195-024-01490-z